Skip to main content

Table 2 Stratified analysis of Glypican genes in The Cancer Genome Atlas database

From: Prognostic value of Glypican family genes in early-stage pancreatic ductal adenocarcinoma after pancreaticoduodenectomy and possible mechanisms

  GPC2 GPC3 GPC5
Low High Adjusted HR
95% CI
Adjusted P
95%CI a
Low High Adjusted HR
95% CI
Adjusted P
95%CI a
Low High Adjusted HR
95% CI
Adjusted P
95%CI a
Age years)
 ≤60 16 22 0.433 (0.119–1.569) 0.202 20 18 1.061 (0.238–4.729) 0.938 18 20 0.197 (0.041–0.951) 0.043
 > 60 40 34 0.415 (0.218–0.790) 0.007 36 38 0.517 (0.280–0.954) 0.035 38 36 0.637 (0.342–1.185) 0.154
Sex
 Female 30 23 0.481 (0.189–1.221) 0.124 28 25 0.381 (0.160–0.909) 0.030 26 27 0.464 (0.200–1.076) 0.073
 Male 26 33 0.302 (0.140–0.652) 0.002 28 31 0.880 (0.372–2.086) 0.772 30 29 0.477 (0.211–1.078) 0.075
Histologic grade
 G1 + G2 39 41 0.374 (0.178–0.787) 0.010 41 39 0.442 (0.222–0.880) 0.020 39 41 0.635 (0.322–1.254) 0.191
 G3 + G4 17 15 0.495 (0.177–1.383) 0.180 15 17 0.644 (0.238–1.743) 0.386 17 15 0.303 (0.105–0.870) 0.026
Radical resectionb
 R0 36 30 0.532 0.249–1.136) 0.103 29 37 0.589 0.293–1.184) 0.137 31 35 0.712 0.346–1.466) 0.357
 R1 + Rx 20 24 0.378
0.162–0.880)
0.024 26 18 0.368
0.135–1.003)
0.051 25 19 0.305
0.120–0.770)
0.012
Radiation therapyc
 No 42 28 0.462 (0.241–0.885) 0.020 37 33 0.504 (0.271–0.938) 0.031 37 33 0.479 (0.254–0.904) 0.023
 Yes 11 19 0.258 (0.068–0.977) 0.046 11 19 0.612 (0.166–2.260) 0.461 12 18 0.725 (0.210–2.498) 0.610
Targeted molecular therapyd
 No 15 14 0.453 (0.187–1.095) 0.079 19 10 0.346 (0.125–0.956) 0.041 16 13 0.397 (0.158–0.995) 0.049
 Yes 38 35 0.477 (0.222–1.027) 0.059 30 43 0.668 (0.328–1.359) 0.265 33 40 0.571 (0.282–1.154) 0.118
  1. Abbreviations: HR hazard ratio, CI confidence interval
  2. a Adjusted for histologic grade, targeted molecular therapy, radiation therapy and radical resection. b Information of radical resection was unavailable in 2 patients. c Information of radiation therapy was unavailable in 12 patients. d Information of targeted molecular therapy was unavailable in 10 patients